DSP 0187
Alternative Names: DSP-0187; JZP-441Latest Information Update: 05 Aug 2024
At a glance
- Originator Sumitomo Dainippon Pharma
- Developer Jazz Pharmaceuticals plc; Sumitomo Pharma
- Class Anxiolytics; Small molecules
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Narcolepsy
Most Recent Events
- 31 Jul 2024 Jazz Pharmaceuticals plans to initiate a phase Ib trial of DSP 0187 in Narcolepsy (PO) in the second half of 2024
- 30 Nov 2023 Suspended - Phase-I for Narcolepsy (In volunteers) in USA (PO)
- 13 Mar 2023 Jazz pharmaceuticals has patent protection for composition of matter patent relating to DSP 0187 (JZP441) in USA and other countries